Physician profile
Daniel A Borman
NPI 1710471024
$737.17
in general payments reported to CMS, 2019-2025
15 companies · $366 in 2025
The $366 reported for 2025 was more than what 89% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $124 · 2022: $24.77 · 2023: $33.74 · 2024: $189 · 2025: $366.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $588.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $588.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $235.48 | 2024-2025 | Tremfya, Stelara |
| Boston Scientific Corporation | $124.08 | 2019 | |
| Madrigal Pharmaceuticals | $91.50 | 2025 | Rezdiffra |
| Abbvie INC. | $52.27 | 2024-2025 | |
| Alcresta Therapeutics, INC. | $33.74 | 2023 | Relizorb |
| Genzyme Corporation | $29.32 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $26.01 | 2024 | Eohilia |
| Travere Therapeutics, INC. | $24.77 | 2022 | |
| Gilead Sciences, INC. | $23.52 | 2025 | |
| Dentsply Ih Ab | $23.29 | 2025 | Navina Rectal Catheter Set Regular |
| Qol Medical, LLC | $16.36 | 2025 | Sucraid |
| Ardelyx, INC. | $15.24 | 2025 | Ibsrela |
| Ipsen Biopharmaceuticals, INC | $14.11 | 2025 | Iqirvo |
| Phathom Pharmaceuticals, INC. | $13.75 | 2025 | Voquezna |
| Ironwood Pharmaceuticals, INC | $13.73 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Borman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.